Author
Ludwig Boltzmann Institute for Hematology and OncologyORCID 0000-0003-0456-5095Unclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Bac Viet Le, Umeshkumar M. Vekariya, Monika Maria Toma…·Tomasz Skórski
This study identifies Polθ as a therapeutic target in DNMT3A-mutated leukemia by showing its essential role in DNA repair and replication fork restart, and demonstrates that its inhibition enhances standard therapies.
Daniel Pölöske, Helena Sorger, Anna Schönbichler…·Richard Moriggl
This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.
Elsa Bernard, Yasuhito Nannya, Robert Paul Hasserjian…·Elli Papaemmanuil
The paper examines TP53 allelic states in MDS patients, finding that bi-allelic targeting is linked to worse outcomes, while mono-allelic targeting does not differ from wild-type patients.